Aurobindo’s Eugia Pharma Gets US FDA Nod To Launch Dasatinib Tablets

Eugia Pharma Specialities Ltd., a wholly owned unit of Aurobindo Pharma Ltd., has received final approval from the US Food and Drug Administration to make and market dasatinib tablets in strengths of 20-140 mg, the company said in an exchange filing.

The product, used to treat adults with Philadelphia chromosome-positive leukemia and acute lymphoblastic leukemia, is expected to be launched in the April-June quarter.

The approved generic had a market size of around $1.8 billion for the 12 months ended February, according to IQVIA data cited by the company.